News

ASCO 2019 News

The theme for this year’s ASCO (American Society of Clinical Oncology) annual meeting was Caring for Every Patient, Learning from Every Patient.  This theme perfectly represents what the meeting is all about. Researchers, doctors and industry from around the world coming together to improve the lives of cancer patients.  Interestingly this meeting is not attended by patients, but instead Patient Advocates attend to share the voice of the patient.   This was my first year attending, and I am happy to report back to you the ‘buzz’ on what is happening with kidney cancer research and treatment.  First up, immunotherapy based combination therapies. Immunotherapy Based Combination Therapies – Presented by Rana McKay, MD, Medical Oncologist, UCSD ...

What is No Tie July?

When it comes to kidney cancer, a tie isn’t good enough. We need a win. Join our month-long fundraising effort, No Tie July, and help us raise one year of life-saving research funding in just one month.

Translocation Renal Cell Carcinoma (tRCC) Research Initiative

Translocation renal cell carcinoma (tRCC) is a rare subtype of renal cell carcinoma occurring in less than 5 percent of patients. Initially found primarily in children, incidence of tRCC found in adults is rising. Because it is so rare, research to identify the best treatments for tRCC patients is severely lacking.  The Translocation RCC Research Initiative (TRRI) is working to change that!  Laura Loughlin, KCCure Director of Patient Engagement, had the opportunity to speak with Dr. James Geller, a tRCC expert at Cincinnati Children’s Hospital and leader of the TRRI. What is the TRRI? The TRRI is a global team of doctors and researchers dedicated to tRCC research to find new and better treatments and improve patient outcomes.  Their work in...

A Day of Kidney Cancer Talk – June 20th – World Kidney Cancer Day

KCCure and Kidney Cancer Canada join forces to bring patients and caregivers A DAY OF KIDNEY CANCER TALK on World Kidney Cancer Day! A DAY OF KIDNEY CANCER TALK is 45-minute “talk” sessions scheduled throughout the day with kidney cancer specialists in Canada, United States and Europe. We’ll be featuring 45 minute sessions throughout the day with experts from the U.S. and Canada. No presentations, no PowerPoint – just you, other members of the RCC community and RCC experts! View the full schedule here. You can join any of the talks at any of the times scheduled during the day with the link details below: Please join my meeting from your computer, tablet or smartphone. https://global.gotomeeting.com/join/292203261  You can also dial in using your phone.  United St...

NIH Clear Cell Kidney Cancer Trial

NIH Trial – HERV-E TCR Transduced Autologous T Cells in People with Metastatic Clear Cell Kidney Cancer.    Good News!  Since I last shared news of this exciting clear cell kidney cancer trial it has continued to actively recruit.  If you are interested there are still spots available.  Eligibility criteria include: Being at least 18, having clear cell RCC, measurable disease progression in the last six months; and being positive for HLA-A 11:01. HLA-A 11:01 is only present in a subset of clear cell RCC patients.  The NIH, at no charge, can arrange testing for you if you are interested in finding out if you are positive for HLA-A 11:01.    Additionally, there are some eligibility requirements related to prior treatments. The trial involves...

KCCURE WELCOMES APPROVAL OF ADDITIONAL COMBINATION THERAPY FOR ADVANCED RENAL CELL CARCINOMA

Washington, DC, ——– – The Kidney Cancer Research Alliance(KCCure) applauds the approval of yet another treatment for advanced renal cell carcinoma by the U.S. Food and Drug Administration (FDA). The latest approved therapy combines EMD Serono’s Avelumab (BAVENCIO) with Pfizer’s axitinib (INLYTA) as first-line treatment for patients with advanced renal cell carcinoma (RCC).  Axitinib, a tyrosine kinase inhibitor, was approved in 2012 as monotherapy for the treatment of second-line renal cell carcinoma. Avelumab is a checkpoint inhibitor that blocks the PD-L1 pathway. This is the second approved treatment combining axitinib with a checkpoint inhibitor. The JAVELIN Renal 101 trial investigated the combination of avelumab and axitinib in comparison to sunitinib (SUTENT) in pr...

KCCURE APPLAUDS FDA APPROVAL OF NEW COMBINATION THERAPY FOR ADVANCED KIDNEY CANCER

Washington, DC, ——– – The Kidney Cancer Research Alliance (KCCure) welcomes the U.S. Food and Drug Administration (FDA) decision to approve pembrolizumab (KEYTRUDA) in combination with axitinib (INLYTA) as first-line treatment for patients with advanced renal cell carcinoma (RCC).   Pembrolizumab is an anti-PD-1 checkpoint inhibitor that helps the immune system detect and fight tumors cells. Axitinib is an anti-angiogenic targeted therapy that inhibits the growth of tumors. This is the first approval of an immunotherapy agent used in combination with a targeted therapy for the treatment of advanced kidney cancer. Axitinib as monotherapy is already approved for patients who have progressed on one line of therapy. The decision by the FDA was based on the...

What’s your Kidney Cancer Song?

Driving the long trip from DC to our Kidney Cancer Patient Meeting in Chapel Hill, North Carolina last week, a song from Pink came on the radio: Walk me home in the dead of night I can’t be alone with all that’s on my mind, So say you’ll stay with me tonight ‘Cause there is so much wrong going on outside I couldn’t help but think about Kidney Cancer Awareness Month and the stories that we’ve been sharing.  A huge part of what we do at KCCure is to help find patients connect with other patients – so that no one feels alone. How many times have you popped into one of our communities in the dead of night?  I know I have.  And I often see a post from someone who is unable to sleep.  Because there is so much going on in their mind. But inevitably, there is someone else w...

KCCure – Making a Difference – Calithera Biosciences

Kidney Cancer clinical trials provide an exciting opportunity to be at the forefront of cancer treatment. In this Making a Difference article, KCCure highlights the work being done by Calithera Biosciences.  Laura Loughlin, KCCure’s Director of Patient Engagement, had the opportunity to speak with Catherine Sunderlin, Senior Medical Science Liaison at Calithera Biosciences to discuss their CANTATA kidney cancer clinical trial and their oncology drug candidate telaglenastat (CB-839).  KCCure:  Thank you for taking the time to meet with us Catherine.  Can you tell us about Calithera Biosciences? Catherine Sunderlin:  Calithera Biosciences is a pharmaceutical company founded in 2010 and based in South San Francisco, CA.  Our vision is to be a fully integrated biotechnology company that ...

ASCO-GU 2019 Patient Perspective on CARMENA

19-02 Survey CARMENA ASCO GU KCCure

New Localized Kidney Cancer Support Group

Have you been diagnosed with localized kidney cancer? KCCure has a new support community just for you. The KCCure 1-2-3 group is a support community for those managing a diagnosis of stage 1, stage 2 or stage 3 kidney cancer. Two thirds of patients will be diagnosed with localized kidney cancer – in other words, renal cell carcinoma in the kidney that has not spread into other organs. For almost all of these patients, the treatment will involve surgery to remove the cancer followed with close observation by their doctor. Despite the fact that most kidney cancer patients fall into this category, few resources exist for them to learn about their disease and connect with others.  Our research shows that kidney cancer patients – regardless of their stage – experience high degrees of anxi...

  • 1
  • 2
  • 7

Lost Password

Register

Subscribe for updates!